New Drug Approved for Neuroblastoma Based on MSKCC Research New Drug Approved for Neuroblastoma Based on MSKCC Research

Naxitamab has been approved for pediatric and adult patients with relapsed/refractory neuroblastoma in the bone and bone marrow that has responded to prior therapy.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news